Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 6/20 | 0.80 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.69 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.69 |
| ▸ | ACP1 | P24666 | 3/20 | 0.69 |
| ▸ | PTPRF | P10586 | 2/20 | 0.69 |
| ▸ | PTPRB | P23467 | 2/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.67 |
| ▸ | MAOA | P21397 | 2/20 | 0.67 |
| ▸ | MAOB | P27338 | 2/20 | 0.67 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.62 |
| ▸ | PIM1 | P11309 | 1/20 | 0.61 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | PPARG | P37231 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15816571 | 1.00 | ENPP2 (0.80) | ENPP2PTPN1PTPN2ACP1PTPRF | |
| SCHEMBL15816573 | 1.00 | ENPP2 (0.80) | ENPP2PTPN1PTPN2ACP1PTPRF | |
| SCHEMBL14564276 | 0.89 | ENPP2 (1.00) | ENPP2PTPN1PTPN2ACP1PTPRF | |
| SCHEMBL15817070 | 0.88 | MAPK1 (0.65) | ENPP2PTPN1PTPN2ACP1PTPRF | |
| SCHEMBL15817069 | 0.88 | MAPK1 (0.65) | ENPP2PTPN1PTPN2ACP1PTPRF | |
| SCHEMBL15817846 | 0.88 | MAPK1 (0.68) | ENPP2PTPN1PTPN2ACP1PTPRF | |
| SCHEMBL15817072 | 0.88 | MAPK1 (0.65) | ENPP2PTPN1PTPN2ACP1PTPRF | |
| SCHEMBL15817851 | 0.88 | MAPK1 (0.68) | ENPP2PTPN1PTPN2ACP1PTPRF | |
| SCHEMBL15817849 | 0.88 | MAPK1 (0.68) | ENPP2PTPN1PTPN2ACP1PTPRF | |
| SCHEMBL15817024 | 0.88 | PTPN1 (0.81) | ENPP2PTPN1PTPN2ACP1PTPRF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115122-B2 | Non-ATP dependent inhibitors of extracellular signal-regulated kinase (ERK) | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2015-08-25 | — | — | US | disclosed |
| US-20140179743-A1 | NON-ATP DEPENDENT INHIBITORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE (ERK) | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179743-A1 | NON-ATP DEPENDENT INHIBITORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE (ERK) | MAPK1, MAP3K1, MAP3K20 | ENPP2 1846/4885PTPN1 230/4885PTPN2 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.